Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention. The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial

Journal of the American College of Cardiology

Volumn 53, Issue 10, 2009, Pages 837-845

  Fung, Anthony Y ^a   Saw, Jacqueline ^a   Starovoytov, Andrew ^a   Densem, Cameron ^a   Jokhi, Percy ^a   Walsh, Simon J ^a   Fox, Rebecca S ^a   Humphries, Karin H ^b   Aymong, Eve ^b   Ricci, Donald R ^a   Webb, John G ^b   Hamburger, Jaap N ^a   Carere, Ronald G ^b   Buller, Christopher E ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

eptifibatide; glycoprotein IIb IIIa inhibitors; platelet; stenting

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HIRULOG; TROPONIN I;

ABBREVIATED INFUSION; ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; INFUSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STANDARD INFUSION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETREATMENT; STENTS;

EID: 60949098494     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.09.060     Document Type: Article

References (32)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
2. Topol E.J., and EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 (1998) 87-92
3. Kong D.F., Califf R.M., Miller D.P., et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98 (1998) 2829-2835
4. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
5. O'Shea J.C., Hafley G.E., Greenberg S., et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial. JAMA 285 (2001) 2468-2473
6. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
7. Kiemeneij F., Laarman G.J., Slagboom T., and van der Wieken R. Outpatient coronary stent implantation. J Am Coll Cardiol 29 (1997) 323-327
8. Koch K.T., Piek J.J., Prins M.H., et al. Triage of patients for short term observation after elective coronary angioplasty. Heart 83 (2000) 557-563
9. Carere R.G., Webb J.G., Buller C.E., et al. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. Am Heart J 139 (2000) 52-58
10. Ziakas A.A., Klinke B.P., Mildenberger C.R., et al. Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study. Am Heart J 146 (2003) 699-704
11. Dorros G., Cowley M.J., Simpson J., and Bentivoglio L.G. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation 67 (1983) 723-730
12. Muller I., Seyfarth M., Rudiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
13. Gawaz M., Seyfarth M., Muller I., et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. (abstr). Am J Cardiol 87 (2001) 332-336
14. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
15. Antman E., Bassand J.-P., Klein W., et al. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol 36 (2000) 959-969
16. Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 38 (2001) 2114-2130
17. Hwang I., and Morikawa T. Design issues in noninferiority/equivalence trials. Drug Info J 33 (1999) 1205-1218
18. Natarajan M.K., Kreatsoulas C., Velianou J.L., Mehta S.R., Pericak D., and Goodhart D.M. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 93 (2004) 750-753
19. Prasad A., Singh M., Lerman A., Lennon R.J., Holmes Jr. D.R., and Rihal C.S. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48 (2006) 1765-1770
20. Selvanayagam J.B., Porto I., Channon K., et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 111 (2005) 1027-1032
21. Porto I., Selvanayagam J.B., Van Gaal W.J., et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 114 (2006) 662-669
22. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
23. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
24. Fox K.A.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial. Circulation 110 (2004) 1202-1208
25. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) 216-235
26. Yatskar L., Selzer F., Feit F., et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 69 (2007) 961-966
27. Bertrand O.F., De Larochelliere R., Rodes-Cabau J., et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 114 (2006) 2636-2643
28. Kleiman N.S., Raizner A.E., Jordan R., et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 26 (1995) 1665-1671
29. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90 (1994) 1757-1764
30. Blankenship J.C., Tasissa G., O'Shea J.C., et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 38 (2001) 653-658
31. Bonz A.W., Lengenfelder B., Strotmann J., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 40 (2002) 662-668
32. Schiano P., and Gabriel Steg P. Measurement and prevention of myocardial injury during percutaneous coronary intervention. Heart 93 (2007) 656-657